Visualization of angiogenesis during cancer development in the polyoma middle T breast cancer model: molecular imaging with (R)-[11C]PAQ

[1]  K. Gelmon,et al.  Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. , 2012, Cancer treatment reviews.

[2]  V. Arango,et al.  Synthesis and in vitro evaluation of [18F](R)-FEPAQ: a potential PET ligand for VEGFR2. , 2012, Bioorganic & medicinal chemistry letters.

[3]  S. Koch,et al.  Signal transduction by vascular endothelial growth factor receptors. , 2012, Cold Spring Harbor perspectives in medicine.

[4]  U. Tateishi,et al.  Radiolabeled RGD peptides as integrin alpha(v)beta3-targeted PET tracers. , 2012, Current medicinal chemistry.

[5]  T. Kniess.  Radiolabeled small molecule inhibitors of VEGFR - recent advances. , 2012, Current pharmaceutical design.

[6]  Xiaoyuan Chen,et al.  Site-Specific Labeling of scVEGF with Fluorine-18 for Positron Emission Tomography Imaging , 2012, Theranostics.

[7]  L. Claesson‐Welsh,et al.  Signal transduction by vascular endothelial growth factor receptors. , 2011, The Biochemical journal.

[8]  G. Sledge,et al.  Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer. , 2011, Bioorganic & medicinal chemistry letters.

[9]  Janusz Emerich,et al.  Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients. , 2011, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[10]  Juri G. Gelovani,et al.  Methodological and practical challenges for personalized cancer therapies , 2011, Nature Reviews Clinical Oncology.

[11]  Alan A. Wilson,et al.  Radiolabeled Small Molecule Protein Kinase Inhibitors for Imaging with PET or SPECT , 2010, Molecules.

[12]  R. Swann,et al.  Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers , 2010, Clinical Cancer Research.

[13]  H. Hollema,et al.  89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922 , 2010, Journal of Nuclear Medicine.

[14]  Kalle Jonasson,et al.  Tissue Profiling of the Mammalian Central Nervous System Using Human Antibody-based Proteomics* , 2009, Molecular & Cellular Proteomics.

[15]  S. Stone-Elander,et al.  Synthesis and preclinical evaluation of [11C]PAQ as a PET imaging tracer for VEGFR-2 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  D. Rimm,et al.  High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. , 2008, Human pathology.

[17]  D. Nolan,et al.  Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis , 2008, Science.

[18]  H. Hollema,et al.  In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft , 2007, Journal of Nuclear Medicine.

[19]  Sanjiv S Gambhir,et al.  PET of vascular endothelial growth factor receptor expression. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  M. Fernö,et al.  Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Kojiro,et al.  Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma , 2004, Cancer.

[22]  A. Lammertsma,et al.  Transport across the blood-brain barrier: stereoselectivity and PET-tracers. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[23]  S. Wedge,et al.  Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. , 2002, Journal of medicinal chemistry.

[24]  P. Larsen,et al.  Synthesis of [11C]iodomethane by iodination of [11C]methane , 1997 .

[25]  L. Ellis,et al.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. , 1995, Cancer research.

[26]  K. Alitalo,et al.  Endothelial receptor tyrosine kinases involved in angiogenesis , 1995, The Journal of cell biology.

[27]  J. Pollard,et al.  Animal Model Progression to Malignancy in the Polyoma Middle T Oncoprotein Mouse Breast Cancer Model Provides a Reliable Model for Human Diseases , 2003 .

[28]  Vascular Biology, Atherosclerosis and Endothelium Biology Vascular Endothelial Growth Factor Localization in the Adult , 2022 .